NeoPharm Inc.
100 Corporate North, Suite 215
Bannockburn
Illinois
60015
United States
Tel: 847-295-8678-Ext-115
Fax: 847-295-8854
111 articles about NeoPharm Inc.
-
Cold Rescue Elements the Perfect Antidote to the Winter Cold Season
2/20/2019
The cold season, which begins in late August and continues until March or April, may be due to schools opening, the colder weather or just because people spend more time indoors.
-
Elements from Neopharm Coming to Vitabeauti.com
1/31/2019
Neopharm brings new product line to popular health and beauty products site
-
Neopharm's Ultimate Joint Elements and Supreme Probiotic Elements Now Available on Amazon
1/28/2019
NeoPharm, the fastest-growing pharmaceutical company in Bulgaria, announced that it now has Ultimate Joint Elements and Supreme Probiotic Elements live on Amazon.
-
Canadian-based NeoPharm Completes Acquisition Of Boston-Based Averica Discovery Services
11/4/2016
-
Canadian-based NeoPharm Completes Acquisition Of Boston-Based Averica Discovery Services
11/3/2016
-
Prima Biomed And NeoPharm Execute Final Agreement For CVac License
2/21/2014
-
Prima Biomed and NeoPharm Enter Into License for CVac in Israel
11/6/2013
-
Apricus Biosciences and NeoPharm Sign Licensing Agreement for Vitaros(R) in Israel for up to $4.35 Million, Plus Royalties
2/14/2011
-
Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm as Chief Development Officer
1/7/2011
-
Dr. Daniel Von Hoff Joins INSYS Therapeutics/NeoPharm As Chief Development Officer
1/6/2011
-
NeoPharm Completes Merger with INSYS Therapeutics
11/10/2010
-
NeoPharm Announces Merger with INSYS Therapeutics
11/1/2010
-
NeoPharm Announces Second Quarter 2010 Financial Results
8/26/2010
-
NeoPharm Announces First Quarter 2010 Financial Results and Clinical Trial Update
6/11/2010
-
NeoPharm Announces FDA Grant of Orphan Drug Designation for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
5/17/2010
-
NeoPharm Starts Enrolling Pancreatic Cancer Patients in Phase II Trial of LE-DT
4/20/2010
-
NeoPharm Announces Fourth Quarter And Full Year 2009 Financial Results
3/18/2010
-
NeoPharm Announces Orphan Drug Application Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
3/10/2010
-
NeoPharm Presents the Phase II Data of Liposome-Entrapped Paclitaxel (LEP) in Patients with Metastatic Breast Cancer
1/6/2010
-
NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary Fibrosis
1/4/2010